Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12836795 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL2508512 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL828637 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL18218758 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL11127403 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL4749529 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL15799168 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL1361856 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL337170 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL337222 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030518-A1 | Acylated insulin | SCIAPS, INC. | 2006-02-09 | — | — | US | disclosed |
| US-6869930-B1 | Acylated insulin | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| US-20040110664-A1 | Acylated insulin | HAVELUND SVEND (DK) | 2004-06-10 | — | — | US | disclosed |
| EP-1132404-A2 | Acylated insulin | NOVO NORDISK A/S (DK) | 2001-09-12 | — | — | EP | disclosed |
| EP-0792290-B1 | ACYLATED INSULIN | NOVO NORDISK AS (DK) | 2001-08-29 | — | — | EP | disclosed |
| US-6011007-A | ZN2+ COMPLEX. | NOVO NORDISK A/S (DK) | 2000-01-04 | — | — | US | disclosed |
| US-5750497-A | WATER SOLUBLITY | NOVO NORDISK A/S (DK) | 1998-05-12 | — | — | US | disclosed |
| EP-0792290-A1 | ACYLATED INSULIN | NOVO NORDISK A/S (DK) | 1997-09-03 | — | — | EP | disclosed |
| WO-1995007931-A1 | ACYLATED INSULIN | NOVO NORDISK A/S (DK) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030518-A1 | Acylated insulin | INSR, BCAT1, SLC1A5 | KMT2A 2109/4885SMN1; SMN2 4471/4885DGKA 2987/4885 |
| US-20040110664-A1 | Acylated insulin | INSR, BCAT1, INSRR | KMT2A 1861/4885SMN1; SMN2 3864/4885DGKA 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.